Dual Incretin Agonist (GLP-1 & GIP) | Weight Loss, Appetite Suppression & Metabolic Research | For Research Use Only

Tirzepatide is a next-generation dual receptor agonist targeting both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This combination offers a powerful approach to fat loss, glycaemic control, and insulin sensitivity, surpassing the effects of GLP-1 agonists like Semaglutide alone.

Ideal for metabolic, obesity, and diabetes research, the 40mg format provides mid-range flexibility for weekly or bi-weekly research dosing, with high purity and stability.

🔍 Key Features

• Dual GLP-1 & GIP Receptor Activation

• Reduces Appetite and Food Intake

• Improves Insulin Sensitivity and Glycaemic Control

• Enhances Fat Metabolism and Body Composition

• Long-Acting Profile Suitable for Weekly Research Use

• Shown to Outperform GLP-1 Monotherapy in Trials

⚙️ Compound Details

• Peptide Name: Tirzepatide

• CAS Number: 2023788-19-2

• Molecular Formula: C₂₂₅H₃₄₀N₆₀O₆₅

• Molecular Weight: ~4813.45 g/mol

• Purity: ≥ 98% (HPLC Verified)

• Form: Lyophilised powder

• Unit Size: 40mg per vial

🧊 Storage & Handling

• Storage (lyophilised): –20°C, in a dry, light-protected environment

• Reconstitution: Use 1–2ml of sterile bacteriostatic water

• Post-Reconstitution: Store at 2–8°C and use within 10–14 days

• Avoid: Heat, direct light, and repeated freeze-thaw cycles

⚠️ For Research Use Only

Tirzepatide – 40mg is intended strictly for scientific and investigational research. It is not for human consumption or therapeutic use.